Indivior
About Indivior
Indivior is a specialist pharmaceutical company headquartered in Slough, focused on treatments for opioid use disorder and addiction.
Milestones
Milestones as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Products & Services
Products and services as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
SUBLOCADE
Monthly buprenorphine extended-release injection; the company's largest product by net revenue.
Source: sec.govSUBOXONE Film
Buprenorphine and naloxone sublingual film for opioid use disorder, sold mainly in the US, Australia and Canada.
Source: sec.govSUBUTEX Tablets
Buprenorphine sublingual tablets, now distributed mainly in Australia, France and Germany.
Source: sec.govPERSERIS
Once-monthly subcutaneous risperidone injection for adult schizophrenia; marketing and promotion have been discontinued.
Source: sec.govPipeline & Regulatory Record
What public registers list for Indivior: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 10 Oct 2026.
How this is matched: register records are linked to this page by the organisation name they carry, here Indivior Europe Limited. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports Indivior Pharmaceuticals, Inc. files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $1.24bn | $97.0m | 7.8% | $210m | 10-K 2026 |
| Dec 2024 | $1.19bn | $107m | 9.0% | $7.0m | 10-K 2026 |
| Dec 2023 | $1.09bn | $116m | 10.6% | −$126m | 10-K 2026 |
| Dec 2022 | $901m | $74.0m | 8.2% | −$44.0m | 10-K 2025 |
R&D is shown as tagged in the filing, which for this company can exclude acquired in-process R&D. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.
Companies registered in Ireland 1 active in the CRO register
| Company | CRO no. | Registered | Last accounts |
|---|---|---|---|
| Indivior Europe Limited LTD - Private Company Limited by Shares | 616151 | 2017 | Dec 2025 |
From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Indivior Pharmaceuticals, Inc. as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.